Skip to Content

Idebenone Approval Status

FDA Approved: No
Generic name: idebenone
Company: Santhera Pharmaceuticals
Treatment for: Duchenne Muscular Dystrophy

Idebenone is a synthetic short-chain benzoquinone and a substrate for the enzyme NAD(P)H:quinone oxidoreductase (NQO1) in development for the treatment of Duchenne Muscular Dystrophy.

Development Status and FDA Approval Process for idebenone

DateArticle
Jun 10, 2015Santhera Update on Pre-NDA Meeting with FDA on Raxone®/Catena® in Duchenne Muscular Dystrophy (DMD)
Sep 25, 2008Publication in European Heart Journal Highlights Potential of Santhera's SNT-MC17/idebenone in Duchenne Muscular Dystrophy

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide